Strong Biogen results set scene for Alzheimer's big reveal

24 July 2018
2019_biotech_test_vial_discovery_big

Shares in East Coast, USA-based Biogen (Nasdaq: BIIB) were up 6% just ahead of the opening bell in New York, after the firm released positive second quarter results on Tuesday.

Headline figures show a 9% increase in revenues from the same quarter last year, at $3.4 billion, handily beating analysts’ forecasts, which were in the range of $3.25 billion.

Following Generally Accepted Accounting Principles (GAAP), the earnings per share figure was up 3% at $4.18, based on net income of $867 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology